XZXiao Zhao

Xiao Zhao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Xiao Zhao has a total of 158 co-authors. Here are the top co-authors by number of shared publications:

  • Keman Cheng

    19 shared publications
  • Guangjun Nie

    National Center for Nanoscience and Technology

    16 shared publications
  • Qingqing Feng

    Beijing Key Laboratory of Nanocarriers for Drug Delivery, National Center for Nanoscience and Technology of China, Beijing, China

    16 shared publications
  • Guangna Liu

    CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety CAS Center for Excellence in Nanoscience National Center for Nanoscience and Technology No.11 Zhongguancun Beiyitiao Beijing 100190 China

    15 shared publications
  • Jie Liang

    CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety CAS Center for Excellence in Nanoscience National Center for Nanoscience and Technology No.11 Zhongguancun Beiyitiao Beijing 100190 China

    15 shared publications
  • Xiaotu Ma

    15 shared publications

Latest Publications

  • Open Access

    Bacterial membrane-derived dual-targeted nanoplatform enables synergistic cuproptosis induction and immune activation for pancreatic cancer therapy

    by Qingqing Feng, Lizhuo Zhang, Yuanqiang Li, Keke Ma, Gaofeng Hu, Hongye Guan, Kaixin Zhang, Xiaoxia Chen, Yan Zhang, Yumeng Pei, et al.

  • Intranasal DNA nanocarrier vaccines with surface-patterned antigens enhance efficacy against respiratory syncytial virus

    by Xiaoyu Gao, Liting Chen, Qingqing Feng, Wei Lv, Peijun Xu, Zetao Yu, Xinwei Wang, Qinyi Zhang, Tianyu Shao, Yichao Lu, et al.

    Although injectable respiratory syncytial virus (RSV) pre-F vaccines are clinically established, effective intranasal alternatives remain elusive. Geometric and surface antigen display properties are critical for respiratory B cell activation, yet lack strategies for systematic optimization. Here we report a library of DNA nanocarriers with controlled dimensions and sizes, aiming to systemically evaluate the influence of geometric properties on intranasal retention. Taking advantage of the precise control on DNA nanocarriers and antigen functionalization, we organized the surface antigen patterns of pre-F monomers on DNA nanocarriers to maximize B cell activation. The optimized DNA nanocarrier-based vaccine elicited humoral immunity in mice comparable to that induced by the clinically approved trimeric mRNA vaccine against RSV, but with greater durability. While intramuscular mRNA vaccines failed to induce effective respiratory mucosal immunity, the intranasal DNA nanocarrier-based vaccine achieved robust local and systemic immune activation, conferring potent protection against RSV infection. This rational design of intranasal RSV vaccines may be a general strategy for testing and advancing potent intranasal vaccines for a range of infectious respiratory diseases.


  • Pterostilbene-loaded nanoparticles enhance tumor immunotherapy by promoting T cell immunity

    by Tianyu Shao, Jiabeini Zhang, Wenna Li, Keman Cheng, Wei Yan, Guanghui Zhu, Ying Zhang, Guangrong Zhu, Zheng Xing, Xiao Zhao, et al.


  • Open Access

    Bacterial Outer Membrane Vesicles in Potentiating Cancer Vaccines: Progress and Prospects

    by Jiabeini Zhang, Tianyu Shao, Fengjiang Qu, Caiyun Bai, Sijie Li, Pin Gao, Wenna Li, Keman Cheng, Xiao Zhao, Zhimin Fan

    Cancer immunotherapy is increasingly moving toward personalized, precision‐based strategies, with cancer vaccines emerging as a promising approach to reshape treatment. However, despite their potential, current tumor vaccines often yield limited clinical responses and subpar immunogenicity, underscoring the urgent need for innovative delivery systems to enhance immune activation. Bacterial outer membrane vesicles (OMVs), which possess natural immunomodulatory properties and impressive engineering flexibility, have attracted attention as versatile platforms for vaccine development and bioengineering applications. This review thoroughly summarizes recent advances in using OMVs to enhance the effectiveness of cancer vaccines. First, we explain the key biological features of OMVs that support their immunotherapeutic potential. Next, we carefully analyze the primary mechanisms by which OMVs enhance immune responses, as well as cutting‐edge engineering strategies to improve their safety, immunogenicity, and specificity. Additionally, we discuss the significant challenges that hinder the clinical use of OMV‐based cancer vaccines and provide a comprehensive review of current progress and future outlooks. Looking forward, combining artificial intelligence, tumor microenvironment profiling, and neoantigen discovery is expected to drive the development of next‐generation, personalized OMV‐based immunotherapies. Overall, OMVs stand out as a transformative platform capable of overcoming major obstacles in cancer vaccine development and pushing forward future cancer immunotherapy.


  • Immunological Conversion of Solid Tumors Using an Outer Membrane Vesicle Based Checkpoint Nanoinhibitor for Cancer Immunotherapy

    by Ming Tang, Wei Lv, Xiaoyu Gao, Chen Xu, Tianjiao Zhang, Bingxin Liang, Xiao Zhao, Hongli Liao, Chong Du, Xiang Li, et al.

    Immune checkpoint blockade therapy has achieved clinical success, yet its efficacy is often limited by a dysfunctional tumor microenvironment. Crucially, the impairment of local innate immune cells directly drives the paucity and dysfunctionality of tumor-specific T cells. To address these issues, this study developed a nanoscale immune checkpoint modulator based on bacterial outer membrane vesicles (OMVs), in which a PD-L1 blockade peptide DPPA-1 is conjugated onto the OMV surface (OMV-DPPA-1), with the outer surface coated with a polyethylene glycol (PEG) layer containing a legumain-responsive substrate to form PEG-OMV-DPPA-1. The modification of PEG not only effectively reduces the immunogenicity of OMV-DPPA-1, thereby bolstering the safety profile of its intravenous deployment and enhancing tumor targeting, but also enables enzyme-triggered controlled release of OMV-DPPA-1. In tumor-bearing mice, PEG-OMV-DPPA-1 not only recruits innate immune cells to alleviate the tumor immune-suppressive microenvironment, transforming immunologically "cold" tumors into "hot" tumors, but also precisely blocks immune checkpoints in the tumor microenvironment, protecting tumor-infiltrating T cells from exhausting. In conclusion, this work illuminates the vast potential of OMVs as an effective immunomodulator that can comprehensively regulate the tumor immune microenvironment to enhance cancer immunotherapy.


  • Engineered Bacterial Therapeutics: Controlled Release Approaches in Oncology

    by Zetao Yu, Ruijie Nie, Wenna Li, Chen Feng, Zhenqi Li, Xiaoyu Gao, Yuting Wang, Rong Liu, Keman Cheng, Xiao Zhao, et al.

    Engineered bacterial therapeutics are gaining attention in tumor therapy, showing significant clinical potential. However, their clinical translation requires stricter regulation of biosafety and targeting specificity. Controlled release systems offer a key strategy to optimize engineered bacteria through precise spatiotemporal gene expression and motility modulation. This review systematically evaluates two core controlled‐release platforms in tumor treatment—tumor microenvironment‐responsive systems and intelligent controllable systems—summarizes representative therapeutic paradigms and critically analyzes the merits and limitations of each. Therefore, this review aims to provide a theoretical foundation for refining controlled‐release strategies in engineered bacteria‐mediated antitumor therapy.


  • Open Access

    Intratumoral microorganisms and artificial antitumor bacteria

    by Wenna Li, Xiaotu Ma, Xiao Zhao

    Intratumoral microorganisms have been detected in multiple cancer types, which can significantly affect the tumor progression and antitumor treatment efficacy. Considering the important role of intratumoral microorganisms in cancer development, novel therapeutic and diagnostic approaches based on living bacteria have received increasing attention in oncology. In addition to wild types, bacteria can also be programmed through synthetic biology techniques to enhance the spatial and temporal controllability. Therefore, once perfected, intratumoral microorganisms can be combined with immunotherapy or other powerful antitumor agents and possibly unlock the next generation of precision cancer diagnosis and therapy. Moreover, the current challenges and perspectives have also been discussed.


  • Top Cited Papers
    Open Access

    Bacterial extracellular vesicles for gut microbiome–host communication and drug development

    by Dingfei Qian, Peijun Xu, Xinwei Wang, Chong Du, Xiao Zhao, Jiaqi Xu


  • Open Access

    Hybrid Outer Membrane Vesicles with Genetically Engineering for Treatment of Implant‐Associated Infections and Relapse Prevention Through Host Immunomodulation

    by Zhichao Wang, Mingfei Li, Wenshuai Li, Liuliang He, Long Wang, Kehan Cai, Xiao Zhao, Yazhou Chen, Daifeng Li

    Implant‐associated infections (IAIs) are refractory to elimination, and the local immunosuppressive microenvironment (IME) exacerbates therapeutic difficulties, ultimately causing persistence and relapse. Therefore, exploring immunostrengthening treatments holds great promise for reversing IME and thoroughly eradicating chronic or repetitive infections. Bacterial outer membrane vesicles (OMVs) have emerged as potential immunostimulatory candidates; however, they lack active targeting capabilities and cause non‐specific inflammatory side effects. In this study, bone marrow‐derived mesenchymal stem cells (BMSCs) are genetically engineered to overexpress CXCR4 and isolated cell membranes (mBMSC CXCR4 ) for hybridization with OMVs derived from Escherichia coli ( E. coli ) to produce nanovesicles (mBMSC CXCR4 @OMV). The resulting mBMSC CXCR4 @OMV nanovesicles demonstrate excellent bone marrow targeting capability and are effectively taken up by bone marrow‐derived macrophages, triggering the efficient transition to pro‐inflammatory M1 status through TLR/NF‐κB pathway. This alteration promotes innate bactericidal capacity and antigen presentation. Subsequent activation of T and B cells and inhibition of myeloid‐derived suppressor cells (MDSCs) facilitated in vivo adaptive immunity in mouse models. Additionally, mBMSC CXCR4 @OMV boosted memory B cell and bacteria‐specific antibody responses. Together, these data highlight the potential of mBMSC CXCR4 @OMV to eradicate complicated IAIs and provide whole‐stage protection against postsurgical relapse, thus marking a significant immunotherapeutic advancement in the post‐antibiotic era.